PURPOSE: We reported recently the induction of selective iodide uptake in prostate cancer cells (LNCaP) by prostate-specific antigen (PSA) promoter-directed sodium iodide symporter (NIS) expression that allowed a significant therapeutic effect of (131)I. In the current study, we studied the potential of the high-energy alpha-emitter (211)At, also transported by NIS, as an alternative radionuclide after NIS gene transfer in tumors with limited therapeutic efficacy of (131)I due to rapid iodide efflux. METHODS: We investigated uptake and therapeutic efficacy of (211)At in LNCaP cells stably expressing NIS under the control of the PSA promoter (NP-1) in vitro and in vivo. RESULTS: NP-1 cells concentrated (211)At in a perchlorate-sensitive manner, which allowed a dramatic therapeutic effect in vitro. After intraperitoneal injection of (211)At (1 MBq), NP-1 tumors accumulated approximately 16% ID/g (211)At (effective half-life 4.6 h), which resulted in a tumor-absorbed dose of 1,580+/-345 mGy/MBq and a significant tumor volume reduction of up to 82+/-19%, while control tumors continued their growth exponentially. CONCLUSIONS: A significant therapeutic effect of (211)At has been demonstrated in prostate cancer after PSA promoter-directed NIS gene transfer in vitro and in vivo suggesting a potential role for (211)At as an attractive alternative radioisotope for NIS-targeted radionuclide therapy, in particular in smaller tumors with limited radionuclide retention time.
PURPOSE: We reported recently the induction of selective iodide uptake in prostate cancer cells (LNCaP) by prostate-specific antigen (PSA) promoter-directed sodium iodide symporter (NIS) expression that allowed a significant therapeutic effect of (131)I. In the current study, we studied the potential of the high-energy alpha-emitter (211)At, also transported by NIS, as an alternative radionuclide after NIS gene transfer in tumors with limited therapeutic efficacy of (131)I due to rapid iodide efflux. METHODS: We investigated uptake and therapeutic efficacy of (211)At in LNCaP cells stably expressing NIS under the control of the PSA promoter (NP-1) in vitro and in vivo. RESULTS: NP-1 cells concentrated (211)At in a perchlorate-sensitive manner, which allowed a dramatic therapeutic effect in vitro. After intraperitoneal injection of (211)At (1 MBq), NP-1 tumors accumulated approximately 16% ID/g (211)At (effective half-life 4.6 h), which resulted in a tumor-absorbed dose of 1,580+/-345 mGy/MBq and a significant tumor volume reduction of up to 82+/-19%, while control tumors continued their growth exponentially. CONCLUSIONS: A significant therapeutic effect of (211)At has been demonstrated in prostate cancer after PSA promoter-directed NIS gene transfer in vitro and in vivo suggesting a potential role for (211)At as an attractive alternative radioisotope for NIS-targeted radionuclide therapy, in particular in smaller tumors with limited radionuclide retention time.
Authors: U Haberkorn; R Kinscherf; M Kissel; W Kübler; M Mahmut; S Sieger; M Eisenhut; P Peschke; A Altmann Journal: Gene Ther Date: 2003-05 Impact factor: 5.250
Authors: U Haberkorn; M Henze; A Altmann; S Jiang; I Morr; M Mahmut; P Peschke; W Kübler; J Debus; M Eisenhut Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: Roisin M Dwyer; Elizabeth R Bergert; Michael K O'connor; Sandra J Gendler; John C Morris Journal: Clin Cancer Res Date: 2005-02-15 Impact factor: 12.531
Authors: Sarah Urnauer; Stephan Morys; Ana Krhac Levacic; Andrea M Müller; Christina Schug; Kathrin A Schmohl; Nathalie Schwenk; Christian Zach; Janette Carlsen; Peter Bartenstein; Ernst Wagner; Christine Spitzweg Journal: Mol Ther Date: 2016-05-09 Impact factor: 11.454
Authors: Kerstin Knoop; Nathalie Schwenk; Patrick Dolp; Michael J Willhauck; Christoph Zischek; Christian Zach; Markus Hacker; Burkhard Göke; Ernst Wagner; Peter J Nelson; Christine Spitzweg Journal: Hum Gene Ther Date: 2013-03 Impact factor: 5.695